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Hyperglycaemia occurs frequently in the critically ill, even in those patients without a history of diabetes. The
mechanisms underlying hyperglycaemia in this group are complex and incompletely defined. In health, the
gastrointestinal tract is an important modulator of postprandial glycaemic excursions and both the rate of gastric
emptying and the so-called incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic poly-
peptide, are pivotal determinants of postprandial glycaemia. Incretin-based therapies (that is, glucagon-like peptide-
1 agonists and dipeptidyl-peptidase-4 inhibitors) have recently been incorporated into standard algorithms for the
management of hyperglycaemia in ambulant patients with type 2 diabetes and, inevitably, an increasing number of
patients who were receiving these classes of drugs prior to their acute illness will present to ICUs. This paper sum-
marises current knowledge of the incretin effect as well as the incretin-based therapies that are available for the
management of type 2 diabetes, and provides suggestions for the potential relevance of these agents in the man-
agement of dysglycaemia in the critically ill, particularly to normalise elevated blood glucose levels.Hyperglycaemia and critical illness: prevalence
and association with adverse outcomes
Both type 1 and type 2 diabetes mellitus (T2DM) in-
crease the propensity for macrovascular and microvascu-
lar disease as well as infection, all of which are likely to
predispose individuals to critical illness necessitating in-
tensive care admission [1]. While the worldwide preva-
lence of formally diagnosed T2DM is about 3% [2], the
prevalence in ICU patients is variably reported as 15 to
20% or even higher [3].
In the critically ill, hyperglycaemia also occurs fre-
quently in patients without known diabetes; this group
includes patients with undiagnosed type 2 diabetes and
those with so-called stress hyperglycaemia. We propose
that the latter should be referred to as critical illness in-
duced hyperglycaemia (CIIH), given that this describes
the pathogenesis more appropriately. Several hormonal
mechanisms appear to be important pathophysiological
mediators of hyperglycaemia during critical illness.* Correspondence: mark.philip.plummer@gmail.com
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© BioMed Central Ltd.2014These mechanisms include increases in counter-regulatory
hormones, such as endogenous glucagon, catechol-
amines and glucocorticoids, inadequate insulin secretion
for the degree of hyperglycaemia and insulin resistance
[4,5]. The exogenous administration of catecholamines,
dextrose, corticosteroids and nutritional support has the
potential to further exacerbate the elevation in blood
glucose [4,6].
CIIH is therefore characterised by hyperglycaemia
(fasting blood glucose ≥7 mmol/l or random blood glu-
cose ≥11.1 mmol/l) in critically ill patients, who were
glucose tolerant prior to their acute illness, and are
shown in the longer term not to have diabetes [1]. The
true prevalence of CIIH is unknown, at least in part be-
cause the vast majority of studies have failed to discrim-
inate it from undiagnosed T2DM [3]. Nevertheless, CIIH
is clearly common – for example, in the NICE-SUGAR
study >60% of patients without known diabetes in the
control arm had blood glucose concentrations >10 mmol/l
requiring exogenous insulin [7].
Marked acute hyperglycaemia is associated with in-
creased morbidity and mortality in the critically ill [8].
The magnitude of the elevation in blood glucose
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to differ between T2DM and CIIH. In observational
studies, a robust association between increased mortality
and hyperglycaemia has been reported consistently in
patients with CIIH, but not in those with pre-existing
T2DM [9-11]. Moreover, preliminary – albeit retrospect-
ive and observational – data suggest that the adverse im-
pact of hyperglycaemia is attenuated or abolished by
pre-existing or chronic hyperglycaemia, and that hyper-
glycaemia during acute illness may, in fact, be protective
[12]. Accordingly, glucose concentrations that are con-
sidered safe in patients with CIIH may well be harmful
in patients with type 1 or (more frequently) type 2 dia-
betes and chronic hyperglycaemia [12]. Furthermore, it
is intuitively logical to tailor strategies for glycaemic
control based on pre-existing glycaemia, rather than
managing all critically ill patients as a homogeneous
group. Prospective studies are urgently required in this
area to clarify these important issues.
The incretin effect – the historical context
The characterisation of the incretin effect arguably
began in 1902 when Bayliss and Starling, with the char-
acterisation of secretin, speculated that the gastrointes-
tinal tract could communicate with the pancreas via a
messenger(s) in the blood [13]. Until that time, primarilyFigure 1 The incretin effect. There is a much greater release of insulin in
administering the same amount of glucose by intravenous (IV) infusion. Su
recorded. The same volunteers returned on a second day and an IV glucos
achieved with the oral load. The difference in the measured plasma insulin
peptide-1 and glucose-dependent insulinotropic polypeptide. Adapted fromas a result of Pavlov’s influence, it was thought that the
functions of the body were regulated exclusively by
nerves. However, it was not until the early 1960s that
the insulin response to enteral glucose was demon-
strated to be much greater than an intravenous glucose
load, despite the latter resulting in substantially higher
blood glucose concentrations [14,15], suggesting that a
hormone (or hormones) secreted from the gastrointes-
tinal tract stimulates insulin secretion. When blood glu-
cose concentrations resulting from oral and intravenous
glucose load were matched, Perley and Kipnis observed
that the plasma insulin response to intravenous glucose
was approximately 40% of that resulting from the oral
glucose load in health, quantifying the magnitude of the
incretin effect for the first time [16] (Figure 1). The hor-
mones responsible for the incretin effect were subse-
quently shown to be glucose-dependent insulinotropic
peptide (GIP) (in 1973) and glucagon-like peptide
(GLP)-1 (in 1985).
GIP is secreted predominantly from duodenal K cells
in response to luminal fat and carbohydrate [17], while
GLP-1 is secreted from intestinal L cells, located primar-
ily in the distal ileum and colon, in response to luminal
fat, carbohydrate, protein and bile acids [18,19]. At least
in health, both GIP and GLP-1 are insulinotropic and, in
the case of GLP-1, glucagonostatic in a strictly glucose-response to oral glucose administration as compared with
bjects were given oral glucose on day 1 with plasma insulin levels
e infusion was titrated to match the plasma glucose excursion
is the incretin effect, mediated by the hormones glucagon-like
[17].
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old of ~8 mmol/l even pharmacological doses of these
hormones have little or no effect on fasting blood glu-
cose [20]. In addition to its insulinotropic and glucago-
nostatic properties, GLP-1 is a physiological modulator
to slow gastric emptying [17,21], while GIP probably has
no effect on gastric emptying and is glucagonotropic
during euglycaemia [22].
Attenuation of the incretin effect and
pathogenesis of hyperglycaemia in type 2
diabetes
In 1986 Nauck and colleagues reported that the magni-
tude of the incretin effect was markedly diminished in
longstanding T2DM [23], and they went on to show that
the insulinotropic effect of GIP is also attenuated in this
group, while that of exogenous GLP-1 is relatively pre-
served [24]. Whether the reduced incretin effect is a pri-
mary phenomenon or epi-phenomenon of β-cell failure
is still uncertain [25], but it is apparent that the reduced
insulinotropic effect of GIP is, in part, an effect of hyper-
glycaemia and, hence, reversible [25]. Nevertheless, these
observations stimulated the development of GLP-1-
based pharmacological therapy for the management of
T2DM. One should recognise that a limitation of these
early studies is that gastric emptying was not quantified.
This is important because the rate of nutrient entry into
the small intestine is a major determinant of both GLP-
1 and GIP secretion [26]. Studies employing direct,
intraduodenal infusion of nutrients indicate that the se-
cretion of GIP and GLP-1 is maintained in both T2DM
[26,27] and the critically ill [28].
Drug development of incretin therapies for the
management of type 2 diabetes mellitus
Initial proof-of-principle studies were performed using
pharmacological doses of GLP-1 administered by intra-
venous or subcutaneous infusion. As well as stimulating
insulin [29] and inhibiting glucagon secretion, both in a
glucose-dependent manner [30], GLP-1 has been shown
to have several important and unique pharmacodynamic
properties that enhance its therapeutic potential. GLP-1
dose-dependently slows gastric emptying, thereby attenuat-
ing postprandial glycaemic excursions [31]. Exogenous
GLP-1 also inhibits appetite, resulting in reduced energy in-
take and sustained weight loss in obese subjects, features
that are beneficial in patients with T2DM [32]. In vitro and
animal studies have shown that GLP-1 exerts trophic effects
on the pancreatic β cells, stimulating proliferation and dif-
ferentiation [33], as well as reducing β-cell apoptosis [34].
Hence, GLP-1 may have the potential to preserve β-cell
mass in patients with type 2 diabetes. Pharmacological ad-
ministration of GLP-1 has significant extra-gastrointestinal
effects with the potential cardioprotective properties ofparticular relevance to the critically ill. For example: in ani-
mal models, GLP-1 attenuates ischaemia-induced myocar-
dial damage [35]; in patients with heart failure, exogenous
GLP-1 has been associated with improvements in left
ventricular ejection fraction, myocardial oxygen uptake and
6-minute walking distance [36]; and when administered
post-coronary artery bypass grafting, GLP-1 is associated
with less use of sympathomimetic drugs and fewer arrhyth-
mias [37]. There is evidence, hitherto derived from animal
studies, that GLP-1 may possess neurotropic effects [38]
which have the potential to be beneficial in the manage-
ment of neurodegenerative conditions such as Alzheimer’s
disease [39]. The implications in the neurocritically ill re-
main uncertain [40,41].
Currently available incretin-based agents for use
in type II diabetes
The administration of GLP-1 to ambulant patients with
diabetes proved clinically impractical. Endogenous GLP-
1 (and its synthetic peptide) has a plasma half-life of
only 1 to 2 minutes [42] due to rapid metabolism by the
ubiquitous, nonspecific enzyme dipeptidyl-peptidase 4
(DPP-4), which forms an inactive metabolite that is rap-
idly cleared by the kidneys [43], necessitating continuous
infusion. The pharmaceutical industry has therefore fo-
cused on the development of stable DPP-4-resistant
GLP-1 receptor agonists, as well as DPP-4 inhibitors that
protect endogenously secreted GLP-1, GLP-2 and GIP
from degradation. DPP-4 inhibitors act as incretin
enhancers, increasing systemic and, perhaps of more
pertinence to their effect, intestinal concentrations of
endogenously secreted GLP-1, GLP-2 and GIP [44].
GLP-1 agonists are incretin mimetics, acting as agonists
at the GLP-1 receptor and, in contrast to DPP-4 inhibi-
tors, do not stimulate GIP or GLP-2 and may reduce en-
dogenous GLP-1 concentrations [45], possibly because
of its effect on gastric emptying [21].
Incretin-based therapies are frequently prescribed and
their use is expected to become even more common,
with recent international guidelines recommending that
GLP-1 agonists and DPP-4 inhibitors be used as part of
standard regimens for patients with T2DM [46].
Glucagon-like peptide-1 receptor agonists
A GLP-1 agonist candidate was fortuitously identified in
the peptide exendin-4 from the salivary venom of the
Gila monster (Heloderma suspectum). The Gila monster
is a slow-moving venomous lizard native to North
America that ingests food 5 to 10 times per year, and in-
gestion results in a substantial increase in plasma
exendin-4 concentrations that may have endocrine func-
tions related to metabolic control in the lizard [47].
Exendin-4 is a peptide with ~50% amino acid sequence
homology to GLP-1 and acts as a full agonist at the
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ism by DPP-4, and is eliminated only by glomerular fil-
tration, with a resultant plasma half-life of 30 minutes
[48]. Exenatide was developed as the synthetic replica of
exendin-4 and in 2005 was the first incretin-based ther-
apy approved by the US Food and Drug Administration.
There are now at least eight GLP-1 agonists undergoing
clinical trials, but twice-daily exenatide, once-daily lixise-
natide, once-daily liraglutide and once-weekly extended-
release exenatide are the only agents to have hitherto
reached the market.
GLP-1 agonists can be categorised as short-acting or
long-acting compounds. All are given subcutaneously
and stimulate fasting insulin secretion and reduce gluca-
gon secretion in a glucose-dependent manner [49].
Dose-dependent nausea, vomiting and diarrhoea occur
frequently, and while it is recognised as a far more
prominent feature of the synthetic agonists when com-
pared with the native peptide, it does decline with time
and is attenuated by dose titration [50,51]. Short-acting
and long-acting compounds do, however, differ in their
effects on fasting and postprandial glucose.
Short-acting glucagon-like peptide-1 agonists
Exenatide and lixisenatide are considered short-acting
GLP-1 agonists and their short half-lives result in large
fluctuations in circulating plasma concentrations [49].
The dominant effect of these drugs on glycaemia is me-
diated by the slowing of gastric emptying, thereby mark-
edly blunting postprandial glycaemic excursions [52].
Patients with diabetes with significant postprandial
hyperglycaemia and relatively well-controlled fasting gly-
caemia therefore achieve the greatest benefit from these
short-acting compounds. Additionally, the combinationTable 1 Marketed incretin-based agents
Therapy Approval D
GLP-1 receptor agonists
Exantide (Byetta®) EMA, US FDA 5
Lixisenatide (Lyxumia®) EMA 1
Extended-release exenatide (Bydureon®) EMA, US FDA 2
Liraglutide (Victoza®) EMA, US FDA 0
DPP-4 inhibitors
Sitagliptin (Januvia®)b EMA,US FDA 2
Vildagliptin (Galvus®)b EMA 5
Alogliptin (Nesina®)b US FDA 2
Saxagliptin (Onglyza®) EMA, US FDA 2
Linagliptin (Trajenta®) EMA, US FDA 5
BD twice daily, DPP-4 dipeptidyl-peptidase-4, EMA European Medicines Agency, MEN
once daily, SC subcutaneous, QW once weekly, US FDA US Food and Drug Administ
clearance <30 ml/minute) and end-stage renal disease. bAvailable in a fixed-dose co
clearance ≥30 to <50 ml/minute), severe and end-stage renal disease.of short-acting GLP-1 agonist and basal insulin confers
complementary effects, with control of fasting hypergly-
caemia by the basal insulin, control of postprandial gly-
caemic excursions with the GLP-1 agonists, a reduction
in glycaemic variability and a low risk of hypoglycaemia
[49].
Exenatide is approved in Europe as adjunctive therapy
in patients with inadequately controlled T2DM who are
taking oral hypoglycaemic agents or basal insulin, or
both. Exenatide has also been approved for use as mono-
therapy in the United States. In February 2013, lixisena-
tide was approved in Europe as adjunctive therapy in
patients with inadequately controlled T2DM, who are
taking oral hypoglycaemic agents or basal insulin, or
both. The pharmacological and pharmacodynamic prop-
erties of these therapies are summarised in Tables 1 and
2, respectively.
Long-acting glucagon-like peptide-1 agonists
Extended-release exenatide and liraglutide are long-
acting GLP-1 receptor agonists that have continuously
elevated plasma concentrations between their recom-
mended dosing intervals. These agonists are approved in
Europe and the United States to be used in the treat-
ment of T2DM as monotherapy or as second-line ther-
apy in combination with oral hypoglycaemic agents.
They achieve higher fasting insulin levels and greater re-
ductions in fasting glucose concentrations [49]. The con-
tinuous activation of the GLP-1 receptor is thought to
induce tachyphylaxis to the deceleration of gastric
emptying, such that the slowing of gastric emptying di-
minishes markedly with long-term use, and consequently
the lowering of postprandial glycaemia is only modest
[53]. Long-acting compounds therefore seem to beose Route Precautions
μg, 10 μg SC, BD Renal impairmenta
0 μg, 20 μg SC, OD Renal impairmenta
mg SC, QW Renal impairmenta
.6 mg, 1.2 mg, 1.8 mg SC, OD MTC of MEN2
5 mg, 50 mg, 100 mg Oral OD Renal iAAmpairmentc
0 mg Oral BD Renal impairmenta
Hepatic impairment
5 mg Oral OD Renal impairmentc
.5 mg, 5 mg Oral OD Renal impairmentc
mg Oral OD –
2 multiple endocrine neoplasia type 2, MTC medullary thyroid carcinoma, OD
ration. aContraindicated in patients with severe renal impairment (creatinine
mbination with metformin. cDose adjustment required in moderate (creatinine
Table 2 Pharmacodynamics: GLP-1 agonists versus DPP-4 inhibitors
GLP-1 agonists DPP-4 inhibitors
Plasma GLP-1 concentrations Pharmacological concentrations of the GLP-1 analogue (sixfold to tenfold
greater than endogenous GLP-1)
Twofold to threefold
increase
Glucose-dependent insulin secretion Yes Yes
Glucose-dependent inhibition of glucagon
secretion
Yes Yes
HbA1c reduction (%) 0.8 to 1.8 0.5 to 1.1
Inhibition of gastric emptying Short acting only No
Postprandial glucose reduction Yes: short acting > long acting Yes (weaker)
Fasting plasma glucose reduction Yes: long acting > short acting Yes (weaker)
Effects on weight Significant weight loss Weight neutral
Inhibition of food intake Yes No
Gastrointestinal adverse effects: nausea,
vomiting and diarrhoea
Common Uncommon
DPP-4 dipeptidyl-peptidase-4, GLP glucagon-like peptide, HbA1c glycated haemoglobin.
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hyperglycaemia in patients with T2DM.
Dipeptidyl-peptidase-4 inhibitors
The DPP-4 inhibitors are orally administered agents and
are approved as monotherapy or in combination with
other oral hypoglycaemic agents for the management of
T2DM. The predominant mechanism of DPP-4 inhibitor
action is thought to be via a gut effect involving local in-
hibition of intestinal DPP-4 activity, stimulation of gut
incretin receptors and activation of gut-to-pancreas
neural pathways, rather than a systemic increase in
incretin plasma concentrations [44]. DPP-4 is expressed
widely throughout the body, including on T lymphocytes
and macrophages, posing a theoretical risk of immune
dysfunction with enzyme inhibition [54]. However, a
meta-analysis reported a very minor increase in all-cause
infection during sitagliptin treatment that was not evi-
dent in studies involving other DPP-4 inhibitors [55].
The reliability and significance of this association re-
mains uncertain. The presentation, dose, contraindica-
tions and pharmacodynamics of the DPP-4 inhibitors
are outlined in Tables 1 and 2.Extra-pancreatic effects of incretin-based therapies
The cardiovascular outcomes of the incretin-based drugs
are currently undergoing assessment in large, multicen-
tre clinical trials [56]. Data from preclinical studies,
short-term single-centre human studies and retrospect-
ive reviews of healthcare claims support a cardioprotec-
tive role for both GLP-1 receptor agonists and DPP-4
inhibitors [57]. The majority of clinical trials have re-
ported reductions in body weight and blood pressure, al-
beit with a mean increase in heart rate of 2 to 4 beats/
minute [57].Finally, there are postmarketing reports of acute pan-
creatitis during use of GLP-1 agonists and DPP-4 inhibi-
tors [58]. However, when compared with health, the risk
of acute pancreatitis is more than doubled in T2DM, in-
dependent of treatment modality [59], and the incidence
of pancreatitis appears to be no greater when starting
these agents than in patients who are commenced on
metformin or a sulfonylurea [60]. For these reasons we
consider the risk of GLP-1-induced or DPP-4 inhibitor-
induced pancreatitis to be negligible. There have also
been concerns, principally from rodent studies, that the
use of incretin-based therapies may be associated with
chronic pancreatitis [61], particularly as this would intui-
tively also increase the risk of pancreatic cancer [62].
Hitherto, these potential risks have not been substanti-
ated [63] and while ongoing postmarketing surveillance
is important, any increase in risk is likely to be extremely
small and is unlikely to be relevant to short-term use in
critically ill patients.
Rationale for the use of glucagon-like peptide-1
as a novel therapy in the critically ill
Administration of intravenous insulin guided by vali-
dated algorithms is the current standard of care for
hyperglycaemic critically ill patients [64]. While the opti-
mal blood glucose for the critically ill remains conten-
tious, concentrations >10 mmol/l should be avoided, at
least for those without pre-existing diabetes and chronic
hyperglycaemia [7]. Several studies have demonstrated
that insulin-induced hypoglycaemia (blood glucose
<2.2 mmol/l) occurs more frequently with intensive in-
sulin therapy and that it is an independent risk factor for
mortality [7,65,66]. Moreover, in the NICE-SUGAR
study, moderate hypoglycaemia (≥2.3 to ≤3.9 mmol/l)
and severe hypoglycaemia (<2.3 mmol/l) were both asso-
ciated with insulin use and increased mortality, with the
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strongest association with death [67]. This observation
may be of particular relevance in neurocritical care, par-
ticularly as there is evidence that systemic glucose con-
centrations even within the normal physiological range
may be associated with cerebral hypoglycaemia and con-
sequent adverse outcomes [68]. These data, accordingly,
strongly suggest that treatment-induced hypoglycaemia
should be avoided.
Regardless of target blood glucose, intravenous insulin
therapy also carries the logistic limitations of frequent
monitoring and training of nursing staff in complicated
protocols. Additionally, increased glycaemic variability
appears to be an independent risk factor for ICU mortal-
ity [69,70] and, although speculative, a therapy that
reduces glycaemic variability may lead to improved
outcomes.
By inhibiting glucagon secretion as well as increasing in-
sulin secretion, GLP-1 or its agonists provide a plausible
pharmacodynamic mechanism to counter the hypergluca-
gonaemia and relative insulin resistance that typifies stress
hyperglycaemia. Furthermore, the cardioprotective proper-
ties hitherto demonstrated in incretin-based therapies are
particularly attractive in the intensive care setting. In animal
models, GLP-1 decreases ischaemia-induced myocardial
damage [35]; in patients with heart failure, exogenous
GLP-1 has been associated with improvements in left
ventricular ejection fraction, myocardial oxygen uptake
and 6-minute walking distance [36]; and when admin-
istered post-coronary artery bypass grafting, GLP-1 is
associated with less use of sympathomimetic drugs and
fewer arrhythmias [37].
For the reasons outlined in Table 3, a simplified ther-
apy for the treatment of hyperglycaemia that avoided iat-
rogenic hypoglycaemia and limited glycaemic variability
would be desirable.
Recommendations for incretin-based therapies in
critically ill patients
Critical illness may markedly affect pharmacokinetics,
particularly for the oral and subcutaneous routes [71].Table 3 Potential benefits of glucagon-like peptide-1
based therapies in the critically ill
Potential benefit
Negligible risk of severe hypoglycaemia
Reduction in insulin requirement
Cardiovascular protection
Attenuated glycaemic variability
Amenable to continuous infusion without dose titration
Decreased blood glucose testing
Simplified protocol for medical and nursing staffFurthermore, multiorgan failure with evolving hepatic
and renal dysfunction and the consequent derangements
in metabolism and elimination may result in unpredict-
able half-lives and drug clearance [71]. For these rea-
sons, and also because of limited experience with these
incretin-based agents, it is appropriate to discontinue
these drugs when critically ill patients are admitted to
the ICU.
In hyperglycaemic patients transitioning from inten-
sive care to ward care, current recommended practice is
to commence scheduled subcutaneous basal-bolus insu-
lin regimens [72], although the American Diabetes Asso-
ciation consensus statement concedes that noninsulin
agents may be appropriate in selected, stable patients
who are expected to consume meals at regular intervals
[72]. There have been no randomised controlled trials to
compare subcutaneous basal-bolus insulin with the
incretin-based agents in this patient group. However, be-
cause of the limitations inherent in basal-bolus insulin
administration, in patients who were on incretin-based
therapies prior to their acute illness and who are im-
proving clinically and transitioning from the ICU to the
hospital ward, recommencement of the established
incretin regimen would be a reasonable therapeutic op-
tion. However, there is limited information available
about the use of incretin-based agents in patients dis-
charged from the ICU. Until such time that the strategy
is formally evaluated, we recommend that intensivists
using such an approach involve an endocrinologist to
provide ongoing care following ICU discharge. A specialist
in the field may also assist by advising dose reduction due
to renal or hepatic impairment (Table 1), managing dose
escalation on recommencing these agents to limit adverse
effects, and being aware of potential interactions with drugs
that have been commenced in the current hospital admis-
sion. Finally, because the glucose-lowering effects of GLP-1
agonists will be diminished in patients with pancreatitis, we
recommend avoiding GLP-1 agonists in patients with a
history of pancreatitis or surgical manipulation of the
pancreas.
Experience using incretin-based therapy in the
critically ill
Hitherto, the use of GLP-1 in the critically ill is limited
to small studies to establish proof of principle [73]. A
limitation of all of these studies has been the short dur-
ation of GLP-1 administration (<72 hours); however, in
patients with T2DM, glucose lowering was maintained
for up to 6 weeks during continuous subcutaneous GLP-
1 infusion [74], suggesting that tachyphylaxis, at least to
the glucose-lowering effect, does not occur. One should
also recognise that while synthetic GLP-1 is currently
prohibitively expensive, there may be a substantial re-
duction in cost should a market become available.
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from 1.2 to 3.6 pmol/kg/minute, marked glucose lower-
ing has been observed in patients with T2DM post-
major surgery [75], post-coronary artery bypass grafting
[37,76] and post-acute myocardial infarction with pri-
mary angioplasty [77]. Our group has evaluated the ef-
fects of GLP-1 infusions in heterogeneous cohorts of
mechanically ventilated patients, both with T2DM and
CIIH [78-80]. GLP-1 infusions at 1.2 pmol/kg/minute
were shown to reduce the glycaemic response to small
intestinal nutrient in mechanically ventilated patients
with chronic hyperglycaemia [80] and to intragastric and
small intestinal nutrient delivery in patients not known
to have T2DM (Figure 2) [78,79]. At this dose, nutrient-
induced hyperglycaemia was attenuated but not sup-
pressed completely, and the effect appears to be more
prominent in patients without a history of T2DM. We
also reported that GLP-1 slows gastric emptying when
emptying is relatively normal, but has minimal effect
when emptying is already delayed, consistent with stud-
ies in ambulant type 2 diabetics [79]. The infusions were
well tolerated in all patient groups and there were no re-
ported episodes of hypoglycaemia.
Administration of intravenous exenatide is also being
explored, as currently these drugs are substantially
cheaper than the synthetic peptide. As outlined (Table 1),
exenatide is only approved for subcutaneous adminis-
tration in the ambulant type 2 patient, but there isFigure 2 Glucose-lowering effect of glucagon-like peptide-1 in critica
glucose excursion in response to small intestinal feeding is markedly attenu
under the curve at 240 minutes: GLP-1, 2,077 ± 145 mmol/l/minute vs. plac
error of the mean (n = 7). Reproduced with permission from [81].experience with its intravenous use in trial settings
[81,82]. Abuannadi and colleagues administered intra-
venous exenatide for 48 hours in an open-label, nonran-
domised, pilot study in 40 cardiac ICU patients [83].
The effectiveness of exenatide was benchmarked to glu-
cose concentrations previously recorded during intensive
and moderate insulin therapies [83]. Mean blood glucose
concentrations with intravenous exenatide were nonin-
ferior to the NICE-SUGAR-endorsed insulin protocol
(that is, moderate), and glycaemic variability was re-
duced [83]. No episodes of severe hypoglycaemia were
reported in the exenatide group, but nausea (40%) and
vomiting (5%) occurred frequently [83]. Whether these
agents could be used as standalone therapy or as
insulin-sparing agents with the benefits of reduced
hypoglycaemia and diminished glycaemic variability re-
mains to be determined. Further studies using the com-
mercially marketed GLP-1 agonists are warranted [84].
While studies in the critically ill have focused on GLP-
1 and its agonists, the role of GIP and DPP-4 inhibitors
also warrants consideration [84]. While it is known that
the insulinotropic effect of GIP is markedly reduced in
T2DM, this may be primarily due to hyperglycaemia ra-
ther than an inherent cellular defect [85]. In the critically
ill, our group demonstrated that exogenously adminis-
tered GIP with concurrent GLP-1 does not lower blood
glucose concentrations, either in the fasted state or in
response to small intestinal nutrient, more than GLP-1l illness. In critically ill patients without known diabetes the blood
ated by 1.2 pmol/kg/minute glucagon-like peptide-1 (GLP-1) (area
ebo, 2,568 ± 208 mmol/l/minute; P <0.01). Data are mean ± standard
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study and further research to clarify whether GIP retains
its insulinotropic effect in critically ill patients, in whom
blood glucose concentrations have only been transiently
elevated, merits further investigation.
The DPP-4 inhibitors have not yet been investigated as
a therapeutic strategy for CIIH. Delayed gastric empty-
ing occurs frequently in critical illness, with absolute
gastroparesis not infrequent [87], and also, at least in
health, hyperglycaemia per se slows gastric emptying
[88]. Accordingly, intragastric administration of an oral
glucose-lowering drug may not be the most effective
route. Nevertheless, in patients with known normal gas-
tric emptying or with post-pyloric administration in pa-
tients with delayed gastric emptying, the local intestinal
mechanism of action supports the study of the renally
safe DPP-4 inhibitor linagliptin as a potential novel oral
agent for glycaemic control in the critically ill.
Conclusions
The discovery of the incretin hormones has encouraged
a burgeoning pharmaceutical industry that exploits the
entero-insular axis. As the prevalence of T2DM and the
use of incretin-based regimens continue to rise, the
intensivist is likely to encounter more patients who were
taking these drugs prior to their acute illness. Presently,
there is little experience with continuing these agents in
acute illness and more study is urgently required.
Nevertheless, the pharmacologic strategy of adminis-
tering incretin mimetics to manage acute hypergly-
caemia in the critically ill, while minimising the risk of
hypoglycaemia and mitigating glycaemic variability, is
appealing. Future studies should focus on the identifica-
tion of the patient groups most likely to benefit from the
administration of incretin receptor agonists, which of
the agents is most useful in the critically ill, and at what
dose, the relevance of the route of feeding with concur-
rent incretin therapy and, finally, whether these agents
should be used in combination with insulin or as single-
agent therapy to provide a safer, more effective and sim-
pler method of achieving glycaemic control.
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